Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wonnemann

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 7, 2000
Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathwaysM Wonnemann, A Singer, W E Müller
Praxis|January 13, 2001
[Mechanism of action of St. Johns wort extract]W E Müller, A Singer, M Wonnemann
Pharmacopsychiatry|August 24, 2001
Hyperforin--antidepressant activity by a novel mechanism of actionW E Müller, A Singer, M Wonnemann
The Journal of Pharmacology and Experimental Therapeutics|August 24, 1999
Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1A Singer, M Wonnemann, W E Müller
Pharmacopsychiatry|August 24, 2001
Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wortM Wonnemann, A Singer, B Siebert, et al.
Pharmacopsychiatry|July 31, 1998
Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extractW E Müller, A Singer, M Wonnemann, et al.
Life Sciences|August 26, 1998
Hyperforin as a possible antidepressant component of hypericum extractsS S Chatterjee, S K Bhattacharya, M Wonnemann, et al.
The Journal of Pharmacy and Pharmacology|December 24, 2002
Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparationsS Kressmann, A Biber, M Wonnemann, et al.
International Journal of Clinical Pharmacology and Therapeutics|January 24, 2006
Significant food interactions observed with a nifedipine modified-release formulation marketed in the European UnionM Wonnemann, B Schug, K Schmücker, et al.
European Journal of Clinical Pharmacology|May 16, 2002
Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfastB S Schug, E Brendel, M Wonnemann, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 7, 2000
Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathwaysM Wonnemann, A Singer, W E Müller
Praxis|January 13, 2001
[Mechanism of action of St. Johns wort extract]W E Müller, A Singer, M Wonnemann
Pharmacopsychiatry|August 24, 2001
Hyperforin--antidepressant activity by a novel mechanism of actionW E Müller, A Singer, M Wonnemann
The Journal of Pharmacology and Experimental Therapeutics|August 24, 1999
Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1A Singer, M Wonnemann, W E Müller
Pharmacopsychiatry|August 24, 2001
Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wortM Wonnemann, A Singer, B Siebert, et al.
Pharmacopsychiatry|July 31, 1998
Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extractW E Müller, A Singer, M Wonnemann, et al.
Life Sciences|August 26, 1998
Hyperforin as a possible antidepressant component of hypericum extractsS S Chatterjee, S K Bhattacharya, M Wonnemann, et al.
The Journal of Pharmacy and Pharmacology|December 24, 2002
Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparationsS Kressmann, A Biber, M Wonnemann, et al.
International Journal of Clinical Pharmacology and Therapeutics|January 24, 2006
Significant food interactions observed with a nifedipine modified-release formulation marketed in the European UnionM Wonnemann, B Schug, K Schmücker, et al.
European Journal of Clinical Pharmacology|May 16, 2002
Dosage form-related food interaction observed in a marketed once-daily nifedipine formulation after a high-fat American breakfastB S Schug, E Brendel, M Wonnemann, et al.
Pageof 2